Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Inclusion Criteria: * Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the trial laboratory. * Participants with one of the following pulmonary TB conditions: DS-TB treatment arm participants should be: * sensitive to rifampicin and isoniazid by rapid sputum based test AND * either newly diagnosed for TB or have a history of being untreated for at least 3 years after cure from a previous episode of TB. DR-TB treatment arm participants should be Resistant to rifampicin and/or isoniazid. * Of non-childbearing potential or willing to practice effective methods of birth control * Body weight (in light clothing and no shoes) ≥ 30 kg. * Completed informed consent form Exclusion Criteria: * Karnofsky score \<60% * Any risk factor for QT prolongation * Any planned contraindicated medicines * Resistant to fluoroquinolones (rapid, sputum-based molecular screening tests). Any of the following lab toxicities/abnormalities: * CD4+ count \< 100 cells/µL (HIV infected participants) * platelets \<75,000/mm³ * creatinine \>1.5 times upper limit of normal (ULN) * eGFR ≤ 60 mL/min * haemoglobin \<8.0 g/dL * serum potassium less than the lower limit of normal for the laboratory. * GGT: greater than 3 x ULN * AST: ≥3.0 x ULN to be excluded; * ALT: ≥3.0 x ULN to be excluded * ALP: ≥3.0 x ULN to be excluded * Total bilirubin: \>1.5 x ULN to be excluded; * Direct bilirubin: greater than 1x ULN to be excluded